This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech M&A is MIA

A Pfizer (PFE - Get Report) proposal to acquire Gilead Sciences (GILD - Get Report) would have been audacious. Expensive? Surely, but merging the largest pharma company with the largest (and hottest) biotech company would have been game changing. Investors would have cheered such a deal. 

Would have... 

Instead, Pfizer is sticking with the tired, mega-pharma merger playbook. It wants to acquire AstraZeneca (AZN - Get Report) in a deal that will likely cost more than $100 billion. AstraZeneca is rebuffing Pfizer's offer for now, but in the coming weeks, we're sure to hear much about how a union of Pfizer and AstraZeneca will yield operational synergies and cost savings, thereby delivering shareholder value.


What strikes me most about this sudden surge in healthcare M&A -- $153.6 billion so far in 2014 NOT counting the Pfizer-AstraZeneca proposal -- is the absence of biotech companies from the equation. No one is bidding for Gilead, Biogen Idec (BIIB) or Celgene (CELG - Get Report).

Instead, Big Pharma seems content to trade assets amongst themselves.  Novartis (NVS) is buying GlaxoSmithKline's (GSK) oncology businesses fort $16 billion while selling its vaccine business back to Glaxo for $7 billion. Then there was Valeant Pharmaceuticals (VRX) offer to buy Allergan (AGN) for $50 billion. 

Biotech M&A is MIA.

Why? Valuation is a problem. Biotech stocks are expensive, even with the recent pullback. From inside the biotech bubble, Alnylam Pharma's (ALNY - Get Report) $6 billion market cap might have looked really cool and a validation of the emerging RNAi therapeutics field. From the outside, paying that much for an unproven technology is viewed as insane. And even with Alnylam's market value cut in half during the biotech stock sell off, there's probably still too much risk there. 

I don't mean to pick on Alnylam only because there are certainly many more speculative, development-stage biotech stocks with too much risk for the lofty price tag. 

Some die-hard biotech believers will say the sector doesn't need Big Pharma takeouts to be successful. The biotech sector can -- and is -- succeeding on its own. That's true. But let's be honest, some boffo biotech M&A would be nice. Right now, we got nothing.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Adam's Tweets

Select the service that is right for you!

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Chris Versace, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Daily Swing Trade

Master swing trader Alan Farley uses his sophisticated software screens to review thousands of stocks each day for you, to find just the handful that meet his demanding criteria.

Product Features:
  • Daily commentary and coaching on swing trading
  • Technical charts and analysis
Top Rated Stocks Top Rated Funds Top Rated ETFs